Lionsgate, Icahn ramp up battle

Both sides campaign over 'poison pill' provision

Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision.

Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.”

Separately, Icahn’s said in a regulatory filing that the poison pill would “frustrate” the ability of Lionsgate shareholders to decide whether to accept Icahn’s offer.

The plan, to be voted on at a May 4 meeting in Toronto, would have the effect of diluting Icahn’s ownership of Lionsgate — currently at 19% — if his holdings top 20%.

Icahn, frustrated by a stagnant stock price, is attempting to buy the 81% of Lionsgate that he doesn’t own at $6 a share via a tender offer that expires April 30. Shares were up a penny to $6.20 in mid-session trading Friday.

Icahn has portrayed the poison pill as “totalitarian.” Lionsgate has repeatedly called Icahn’s offer “financially inadequate and coercive.”

The Glass Lewis report said, “In this case, although the Rights Plan does not contain qualifying offer provisions, in our view, the permitted bid provisions adequately ensure that shareholders are able to consider a reasonable offer for the company. Further, we note that the Rights Plan will expire in three years. In light of these shareholder-friendly provisions, we believe that the Rights Plan may serve to protect Shareholder interests in the event that a takeover bid does not reflect the full value of the company’s shares or is coercive.”

Icahn, in a filing Thursday with the Securities and Exchange Commission, noted that Lionsgate had never adopted a shareholder rights plan.

“The Icahn Group believes that the Poison Pill seriously prejudices the interests of Lionsgate shareholders by precluding them from exercising their fundamental right to decide whether to tender their Lionsgate shares to the Icahn Offer,” it added.

Lionsgate contended in its announcment that the plan is intended to protect Lionsgate and its shareholders from “unfair and coercive” attempts to take over the company. It also said that the plan “enables Lionsgate to continue to execute on its current plans to build shareholder value.”

Shares of Lionsgate – home to “Precious” and the Saw and Tyler Perry franchises along with “Mad Men” and “Weeds” — have been depressed partly by uneven performance of its film slate. “Tyler Perry’s Why Did I Get Married Too” has performed respectably and topped $36 million in domestic grosses in its first six days.

More Film

  • Bob Iger Rupert Murdoch

    Disney-Fox Will Be Global Powerhouse, Especially in Asia and Europe

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • X-Men Can Team With Avengers Thanks

    Fantastic Four, X-Men Can Team With Avengers Thanks to Fox, Disney Deal

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • MICA: Film Tank Pitches Genre Thriller

    MICA: Mexico's Film Tank Pitches to the Small Screen with Genre Thriller 'Dead Days’

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Berlin Film Festival Berlinale

    Asian Brilliant Stars Take Wider Perspective for Second Edition

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Australian Animation ‘Arkie’ Sold to Vision

    Australian Animation ‘Arkie’ Sold to Vision for China Release

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • CineAsia Hands Out Prizes as Hollywood

    CineAsia Hands Out Prizes as Hollywood Mega-Deal Looms

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Spurlock, Jacir, Cooke, Yousra, El Ganainy

    Spurlock, Jacir, Cooke, Yousra, El Ganainy at Variety Studio Dubai

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

More From Our Brands

Access exclusive content